HPLC, LC/TOF, LC/HRMS, LC/MS, LC/MS/MS
IndustriesProteomics
ManufacturerWaters
Importance of the Topic
Therapeutic oligonucleotides demand precise structural confirmation, molecular weight verification, and impurity profiling to ensure safety and efficacy. High-resolution mass spectrometry coupled with liquid chromatography and UV detection offers a comprehensive platform for identity confirmation, impurity screening, and full-sequence verification, supporting drug development and quality control.
Objectives and Study Overview
This application note presents the development of an integrated LC-MS workflow for oligonucleotide analysis, combining reversed-phase UPLC, tunable UV detection, high-resolution time-of-flight MS, and automated data processing. The key aims were to optimize chromatographic separation, minimize salt adduct formation, achieve low detection limits, and enable high-throughput impurity profiling and MS/MS ladder sequencing.
Methodology and Instrumentation
The workflow employs:
- ACQUITY UPLC H-Class Bio System with Waters Oligonucleotide BEH C18 column at 60 °C
- ACQUITY UPLC Tunable UV Detector set at 260 nm
- Xevo G2-XS QTof Mass Spectrometer in negative-ion ESI mode
- MassLynx v4.1 for instrument control and data acquisition
- ProMass HR integrated with MassLynx for spectral deconvolution and automated reporting
Mobile phases consist of 15 mM triethylamine and 400 mM HFIP in water or methanol, prepared gravimetrically. MS settings: 400–3000 Da range, cone voltage 80 V for MS, 120 V for MS/MS, desolvation at 500 °C.
Key Results and Discussion
- Chromatographic separation of polyT standards (15–35 nt) achieved baseline resolution of full-length and truncation products.
- MS spectra exhibited minimal sodium adducts (< 5%) and clear isotopic envelopes, with average monoisotopic mass accuracy of ~1.25 ppm.
- Limit of detection for the polyT standard was determined at 20 fmol on-column, with UV detection as the limiting factor.
- Automated batch processing of 48 samples demonstrated clear identification of target oligonucleotides, single-base deletion/insertion impurities, and color-coded HTML reporting.
- MS/MS ladder sequencing of a 21-nt siRNA strand provided full C and Y ion series coverage, confirming sequence identity through deconvoluted fragment matching.
Benefits and Practical Applications
This integrated workflow streamlines oligonucleotide analysis by combining high-resolution mass accuracy, robust chromatography, and automated data processing. It supports high-throughput impurity screening, precise quantification via UV absorbance, and full-sequence MS/MS confirmation, making it suitable for R&D labs, quality control, and biopharmaceutical production.
Future Trends and Opportunities
Advances may include deeper integration with laboratory information management systems, enhanced algorithms for post-translational and chemical modification mapping, application to increasingly complex oligonucleotide formats (e.g., locked nucleic acids, conjugates), and expanded high-throughput capabilities for large library screening.
Conclusion
The described LC-MS workflow offers a robust, sensitive, and fully automated approach for comprehensive oligonucleotide characterization. Its high resolution, low detection limits, and advanced informatics enable reliable impurity profiling and full-sequence verification, addressing critical needs in therapeutic oligonucleotide development and quality control.
References
- Waters Application Note 720005557EN. Routine LC-MS Analysis of Intact Antibodies.
- Waters Application Note 720005378EN. High Sensitivity Intact Mass Analysis of Antibodies (IgG1) Using ionKey/MS.
- Waters Application Note 720005399EN. A Streamlined Data Dependent Acquisition Peptide Mapping Workflow.
- Waters Application Note 720004619EN. Biopharmaceutical Platform Solution with UNIFI for Glycan Analysis.
- Waters Application Note 720005632EN. Adding Mass Detection to Synthetic Oligonucleotide Analyses with the ACQUITY QDa Detector.
- Waters Application Note 720005681EN. High-throughput Screening of Oligonucleotides for Identity and Purity Assessment.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.